If you have been reading about somatotroph and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-02-26. Where a claim depends on a specific study, the study is described rather than over-claimed.
Whether the drug improves hard clinical outcomes is not settled. No completed trial has shown a reduction in heart attacks or strokes among treated patients, although a dedicated cardiovascular outcomes study has been discussed in the literature. Investigators have also examined hepatic fat in people with HIV and fatty liver disease, cognitive measures in small cohorts, and changes in bone density. Regulatory labeling emphasizes monitoring of insulin-like growth factor 1 because supraphysiologic levels raise questions about tissue growth, and the clinical significance of that signal remains an open question rather than a demonstrated harm.
Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized cake in single-use vials |
| Solubility class | Freely soluble in water | Reconstituted with sterile diluent before injection |
| Typical storage temperature | 2 to 8 degrees Celsius | Before reconstitution; protect from light |
| Typical analytical method | Reversed-phase high-performance liquid chromatography | Purity and related-substance testing |
| Identity confirmation | Mass spectrometry | Observed mass near 5.1 kDa for the intact peptide |
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
质量控制项目一般包括外观、身份、纯度、含量、有关物质、水分和微生物限度。身份确认可通过肽图谱、氨基酸分析和质谱完成，纯度则用面积归一化法计算。研究级材料与药品级材料的要求不同，前者常缺少完整药典验证。不同批次间杂质谱是否影响活性，仍是一个需要具体数据回答的问题。
特沙莫瑞林的检测通常依赖反相高效液相色谱和质谱联用。反相色谱可分离肽主峰与缺失序列、氧化产物等杂质，质谱则提供精确质量以确认身份。对于复杂基质中的定量，常采用液相色谱-串联质谱，并配合固相萃取或蛋白沉淀。生物样品中的肽易降解，因此采集和处理条件会影响结果。
== Natural occurrences == Synephrine, although already known as a synthetic organic compound, was first isolated as a natural product from the leaves of various Citrus trees, and its presence noted in different Citrus juices, by Stewart and co-workers in the early 1960s. A survey of the distribution of synephrine amongst the higher plants was published in 1970 by Wheaton and Stewart. It has subsequently been detected in Evodia and Zanthoxylum species, all plants of the family Rutaceae. Trace levels (0.003%) of synephrine have also been detected in the dried leaves of Pogostemon cablin (patchouli, Lamiaceae). It is also found in certain cactus species of the genera Coryphantha and Dolichothele. However, this compound is found predominantly in a number of Citrus species, including "bitter" orange varieties.
Westbrook* (1968), writer, son of syndicated columnist Sheilah Graham Westbrook Phillip Lopate (1964), essayist and fiction writer Ron Padgett (1964), poet and translator, winner of the Shelley Memorial Award in 2009 and Robert Frost Medal in 2018 Steven Millhauser (1965), novelist and winner of the Pulitzer Prize for Fiction for Martin Dressler: The Tale of an American Dreamer Aaron Fogel (1967), poet Eric Van Lustbader (1967), espionage and thriller novelist, writer of Jason Bourne novels Thomas Hauser (1968), author of nonfiction and biographer David Shapiro (1968), poet, literary critic, professor at William Paterson University Hilton Obenzinger (1969), novelist, poet, history and criticism writer Paul Auster (1970), postmodern writer; author of The New York Trilogy, Moon Palace, and the Brooklyn Follies Bob Holman (1970), poet and activist identified with the oral tradition David Lehman (1970), poet, editor of The Best American Poetry series Joshua Rubenstein (1971), writer, winner of a National Jewish Book Award in 2002 Alex Abella (1972), Cuban-American writer Brad Gooch (1973), writer, professor of English at William Paterson University John Prados (1973), author and historian on World War II and the Cold War Todd McEwen (1975), writer, professor at the University of Kent Stephen O'Connor (1975), writer and professor at Sarah Lawrence College Damien Bona (1977), chronicler of the Academy Awards Mason Wiley (1977), co-author of The Official Preppy Handbook Kevin Baker (1980), novelist and freelance journalist Jeffrey Harrison (1980), poet who won the 1988 Amy Lowell Poetry Travelling Scholarship Lou Antonelli (1981), science fiction writer Douglas Sadownick (1981), writer and psychologist Michael Friedman (1982), novelist and author Michael Azerrad (1983), author, journalist, musician Thomas Dyja (1984), writer, historian, winner of the 1997 Casey Award David Rakoff (1986), comedic essayist Louise Wareham Leonard (1987), writer Al Weisel (1987), freelance writer Adrienne Brodeur (1988), author, program director at Aspen Institute Glen Hirshberg (1988), author, recipient of the 2007 Shirley Jackson Award Adam Mansbach (1988), author and former professor of literature at Rutgers University–Camden Darryl Pinckney (1988), novelist, playwright, and essayist Mako Yoshikawa (1988), novelist, professor at Emerson College Ben Coes (1989), author of political thriller and espionage novels Wade Graham (1989), author, historian, environmentalist G. Winston James (1989), poet, author, activist Robert Salkowitz (1989), author on technology innovation Carol Guess (1990), novelist and poet; professor at Western Washington University John Reed (1990), novelist; author of Snowball's Chance David S. Levinson (1991), short-story writer and novelist Robert Kolker (1991), writer, author of Hidden Valley Road Kelly Link (1991), Hugo Award-winning author; founder of Small Beer Press; editor of St. Martin's Press's Year's Best Fantasy and Horror Loren Goodman (1991), postmodern poet, professor at Underwood International College Andrew Carroll (1992), author, editor, activist, and historian Jordan Davis (1992), poet John Bemelmans Marciano (1992), children's book author and illustrator, grandson of Ludwig Bemelmans, author of Madeline Marie Mutsuki Mockett (1992), writer Melissa de la Cruz (1993), writer known for work in young adult fiction Jay Michaelson (1993), writer and LGBTQ activist Maxine Swann (1994), fiction writer Robert Westfield (1994), writer who won two Lambda Literary Awards Megan McCafferty (1995), chick lit writer, Jessica Darling series, which were plagiarized by Kaavya Viswanathan Tova Mirvis (1995), author Saleemah Abdul-Ghafur (1996), author and Islamic activist Fredrik Stanton (1996), author of Great Negotiations and former publisher for the Columbia Daily Spectator Aravind Adiga (1997), Man Booker Prize-winning novelist Jamel Brinkley (1997), author, winner of the 2018 Ernest J. Gaines Award for Literary Excellence John Coletti (1997), author Gotham Chopra (1997), author, son of health advocate Deepak Chopra Lauren Grodstein (1997), author, professor of Rutgers University–Camden Abdi Nazemian (1998), Iranian-American author, winner of the 2017 Lambda Literary Award for Debut Fiction Trevor Shane (1998), writer Daniel Alarcón (1999), novelist Katherine Howe (1999), novelist, author of The Physick Book of Deliverance Dane Rebecca Pawel (1999), author of mystery novels; winner of the 2004 Edgar Allan Poe Award for Best First Novel Alex Marzano-Lesnevich (2001), author, winner of a 2018 Lambda Literary Award and Chautauqua Prize Fiona Sze-Lorrain (2003), French writer, poet, translator, musician Ben Dolnick (2004), writer, son of biographer Edward Dolnick, member of the Ochs-Sulzberger family that owns The New York Times Danielle Valore Evans (2004), fiction writer Adam Gidwitz (2004), author of best selling children's books Alaya Dawn Johnson (2004), author and winner of the 2015 Andre Norton Award Tongo Eisen-Martin (2004), poet laureate of San Francisco Sidik Fofana (2005), public school teacher and writer, winner of a 2023 Whiting Award Victoria Loustalot (2006), writer of memoir and essays Crystal Hana Kim (2009), writer, If You Leave Me Morgan Parker (2010), poet and Cave Canem Fellow Rachel Heng (2011), Singaporean writer Ben Philippe (2011), author, screenwriter, recipient of the 2020 William C. Morris Award Rowan Hisayo Buchanan (2012), British-American writer, recipient of the Betty Trask Award and the Authors' Club Best First Novel Award Sylvia Khoury (2012), writer and playwright, recipient of a 2021 Whiting Award Yanyi (2013), poet
Comorbid factors that can lead to ischemia are especially likely to contribute to chronic wounds. Such factors include chronic fibrosis, edema, sickle cell disease, and peripheral artery disease such as by atherosclerosis. Repeated physical trauma plays a role in chronic wound formation by continually initiating the inflammatory cascade. The trauma may occur by accident, for example when a leg is repeatedly bumped against a wheelchair rest, or it may be due to intentional acts. Heroin users who lose venous access may resort to 'skin popping', or injecting the drug subcutaneously, which is highly damaging to tissue and frequently leads to chronic ulcers. Children who are repeatedly seen for a wound that does not heal are sometimes found to be victims of a parent with Munchausen syndrome by proxy, a disease in which the abuser may repeatedly inflict harm on the child in order to receive attention. Periwound skin damage caused by excessive amounts of exudate and other bodily fluids can perpetuate the non-healing status of chronic wounds. Maceration, excoriation, dry (fragile) skin, hyperkeratosis, callus and eczema are frequent problems that interfere with the integrity of periwound skin. They can create a gateway for infection as well as cause wound edge deterioration preventing wound closure.
==== Indications ==== Dronabinol, also known as tetrahydrocannabinol (THC), is a natural compound extracted from plants. It is available as Marinol® and Syndros®. It is used as an appetite stimulant in anorexia-associated weight loss in HIV/AIDS patients. An increase in patients' appetite and daily calorie intake with minimal improvement in weight and nausea is reported. Dronabinol is also indicated for chemotherapy-induced nausea and vomiting in cancer patients failing to respond to conventional antiemetics. Dronabinol is also used for cancer-related chronic pain in Europe.
=== October === 1 October – John Braggins, botanist and bryologist (University of Auckland, Auckland War Memorial Museum) (born 1944). 2 October – Mac Gardner, clinical geneticist (University of Otago, University of Melbourne) (born 1942). 4 October – Gordon Keys, atmospheric scientist (DSIR, NIWA), Royal Society of New Zealand Science and Technology Silver Medal (1995) (born 1930). 6 October – Margaret, Lady Liley, paediatrician, general practitioner and farmer (born 1928). 7 October – Graham Bell, police officer and television presenter (Police Ten 7) (born 1946). 8 October – Wally Yovich, businessman, local politician and philanthropist, Whangārei District Councillor (1989–1995) (born 1939). 9 October – Cliff Tait, aviator, politician and writer, Hamilton City Councillor (1992–1995) (born 1929). 10 October – Roger Harris, cricketer (Auckland, national team) (born 1933). 11 October – Richard Nottage, diplomat and public servant, ambassador to Indonesia (1980–1982) and Japan (1987–1988), permanent representative to the UN in Geneva (1984–1987), Secretary of Foreign Affairs and Trade (1991–1999) (born 1939). 15 October – Jim Bolger, politician, MP for King Country (1975–1996) and Taranaki-King Country (1996–1998), Minister of Labour (1978–1984), leader of the National Party (1986–1997), Prime Minister (1990–1997), Ambassador to the United States (1998–2002), chancellor of the University of Waikato (2007–2019), Privy Counsellor (since 1991), Member of the Order of New Zealand (since 1997) (born 1935). 20 October – So You Think, Hall of Fame Thoroughbred racehorse, W. S.
Sources: en.wikipedia.org
Free nerve ending A type of unencapsulated nerve ending that detects pain, temperature, and crude touch. These are the most common type of cutaneous receptors. Frontal lobe A region of the cerebral cortex involved in decision-making, planning, motor function, problem-solving, and aspects of personality. Located at the front of each cerebral hemisphere. Frontal eye fields A region in the frontal lobe involved in voluntary eye movements and visual attention. It plays a role in saccadic control and visual tracking. Functional connectivity A measure of how different brain regions interact during rest or tasks, often assessed using fMRI or EEG by examining correlations in activity over time. Functional magnetic resonance imaging (fMRI) A neuroimaging technique that measures brain activity by detecting changes in blood oxygenation (BOLD signal). It is used to study brain function in real time. Fusiform gyrus A brain region located in the temporal and occipital lobes involved in high-level visual processing, including facial recognition and object categorization. Fusiform face area (FFA) A specialized part of the fusiform gyrus that responds selectively to faces. It is often studied in the context of prosopagnosia (face blindness) and visual expertise.
At the beginning of sleep, a patient is in light sleep with no loss of tone in the throat muscles. Airflow is laminar and soundless. As the upper airway collapses, the obstruction becomes increasingly apparent with the initiation of noisy breathing as air turbulence increases, followed by gradually louder snoring as a Venturi effect forms through the ever-narrowing air passage. The patient's blood-oxygen saturation gradually falls until sleep noise stops, signifying total airway obstruction. This may last for several minutes. Eventually, the patient must at least partially awaken from deep sleep into light sleep, automatically regaining general muscle tone. This switch from deep to light to deep sleep can be recorded using ECT monitors. In light sleep, muscle tone is near normal, the airway spontaneously opens, normal noiseless breathing resumes, and blood oxygen saturation rises. Eventually, the patient reenters deep sleep, upper airway tone is lost, the patient enters the various levels of noisy breathing, and airway blockage returns. The cycle of muscle tone loss and restoration, coinciding with periods of deep and light sleep, repeats throughout the patient's sleep period. The number of apnoea and hypopnoea episodes during any given hour is counted and given a score. If a patient has an average of five or more episodes per hour, mild OSA may be confirmed. An average of 30 or more episodes per hour indicates severe OSA.
=== Example of sarcoma immunology research: the Immunological Constant of Rejection === When the immunological constant of rejection signature (ICR) was retrospectively applied ICR to 1455 non-metastatic STS and searched for correlations between ICR classes and clinicopathological and biological variables; thirty-four per cent of tumors were classified as ICR1, 27% ICR2, 24% ICR3, and 15% ICR4. These classes were associated with patients' age, pathological type, and tumor depth, and an enrichment from ICR1 to ICR4 of quantitative/qualitative scores of immune response. ICR1 class was associated with a 59% increased risk of metastatic relapse when compared with ICR2-4 class. In multivariate analysis, ICR classification remained associated with metastasis-free survival, as well as pathological type and Complexity Index in Sarcomas (CINSARC) classification, suggesting independent prognostic value. ICR signature is independently associated with postoperative MFS in early-stage STS, independently from other prognostic features, including CINSARC. A robust prognostic clinicogenomic model integrating ICR, CINSARC, and pathological type, and suggested differential vulnerability of each prognostic group to different systemic therapies.
Creatine ( or ) is an organic compound that facilitates recycling of adenosine triphosphate (ATP) in vertebrates, primarily in their muscle and brain tissue. It is a popular dietary supplement. Its phosphorylated form, phosphocreatine, donates phosphate groups to adenosine diphosphate (ADP), turning it back into ATP. Creatine also acts as a buffer. It has the nominal formula (H2N)(HN)CN(CH3)CH2CO2H. In solutions, it exists in various tautomers, including a neutral form and zwitterionic forms.
In 1985, the FDA further required a boxed warning to be added, but the problem grew with an estimated 1000 birth defects attributed to the drug by early 1988. While an advisory committee of pediatricians and Centers for Disease Control and Prevention (CDC) staff advised the FDA to restrict Accutane prescriptions, the FDA instead required Roche to expand its warnings of potential side effects and provide informed consent forms to doctors. In 2000, the CDC reported that Roche's Pregnancy Prevention Program of providing contraception counseling and pregnancy testing for women prescribed Accutane was ineffective. The revamped "Targeted Pregnancy Prevention Program" advised women to use two kinds of contraceptives and two pregnancy tests while requiring doctors to directly provide prescriptions to pharmacists to limit off-label use. After Representative Bart Stupak's son committed suicide while taking Accutane in May 2000, Congress held hearings in which some dermatologists attested to Accutane's efficacy in reducing acne and its associated stigma, while others petitioned the FDA for further restrictions of its use. In 2001, the FDA announced the System to Manage Accutane Related Teratogenicity (SMART), which required Roche to train doctors for a sticker-based system of verifying that female patients took pregnancy tests before using Accutane. SMART was replaced by the iPLEDGE program in March 2006. In February 2002, Roche's patents for isotretinoin expired, allowing generic drugs to enter the market.
Sources: en.wikipedia.org
It mimics a natural hypothalamic signal that tells the pituitary to release growth hormone. The result is a rise in circulating growth hormone and, indirectly, in insulin-like growth factor 1. Over weeks of treatment this shift is associated with a selective decrease in fat stored inside the abdomen.
The primary measure is usually a cross-sectional abdominal scan that separates internal fat from fat just under the skin. Waist circumference and body weight are recorded as secondary measures because they are easy to obtain but do not distinguish the two fat compartments. Hormone and metabolic blood tests are collected alongside the imaging.
Available follow-up data indicate that visceral fat drifts back toward pretreatment levels once injections stop. The change is therefore best described as treatment-dependent rather than permanent. Investigators continue to debate whether intermittent or repeated courses would preserve any benefit.
The principal difference is a chemical cap on the N-terminal tyrosine that prevents rapid enzymatic cleavage. Native GHRH is degraded within minutes in plasma, whereas the modified peptide persists considerably longer. The amino acid backbone otherwise mirrors the natural hormone.